PARIS:Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic.
The announcement on Friday, which highlighted the challenges of developing shots at record speed, hinders efforts to develop the multiple options that experts say the world needs to counter a disease that has killed over 1.5 million people.
The news, which came on the same day as Australia axed a domestic vaccine project, is also a blow for many governments that have booked hundreds of millions of doses of the shot, including the European Union, United States and Britain.
Shares in France's Sanofi were down 2.8% at 0910 GMT while Britain's GSK was up 0.2%.
The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine by the end of 2021.
The setback affects one of the most established technologies in vaccines - used against the human papillomavirus, hepatitis B and pertussis among other pathogens - which aims to introduce lab-made proteins into the body to prod the immune system into developing a targeted defence against the novel coronavirus.
It cements the lead of more novel approaches used by vaccines from the likes of Pfizer-BioNTech and Moderna, which use mRNA genetic technology to trick the body into producing those proteins. Both of those shots were found to be about 95% effective in successful large-scale trials.
Delays and additional trials are not unusual but the Sanofi/GSK announcement highlights the unique set of challenges facing drugmakers in multitasking science, speed and logistics during a pandemic that has crushed global economies.
It also underscores why governments have spread their bets by securing shots from different developers.
Australia, meanwhile, cancelled the production of a COVID-19 vaccine developed by the University of Queensland and using an adjuvant made by biotech firm CSL after trials showed it could interfere with HIV diagnosis.
"Science cannot be all about producing positive results; negative results will and must occur," said Diego Silva, an expert at the University of Sydney School of Public Health.
"Negative results are also as important as success in science, since they, too, form part of the evidence base for future research."
DELAYED TO LATE 2021
Sanofi said Friday's results from Phase I/II trials showed "an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen".
"With this type of vaccine, the result is not a surprise, we know that more antigen is needed in older patients. But when in Phase I and II, drugmakers test tolerance and one cannot test strong dosages," said Jean-Daniel Lelievre, head of clinic immunology and infectious diseases at Henri-Mondor hospital in Creteil, France.
"I would think Sanofi and GSK will be able to improve their vaccine."
Phase III studies were expected to start this month. However Sanofi said it would instead launch a phase 2b study in February.
"The study will include a proposed comparison with an authorized COVID-19 vaccine," the company said, declining to give further details on this.
"If data are positive, a global Phase III study could start in Q2 2021. Positive results from this study would lead to regulatory submissions in the second half of 2021, hence delaying the vaccine's potential availability from mid-2021 to Q4 2021."
The two companies said they had "updated governments and the European Commission where a contractual commitment to purchase the vaccine has been made".
BRITAIN JUMPS AHEAD
The vaccine uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK.
Sanofi and GSK have scaled up manufacturing in order to be ready to produce up to one billion doses of their vaccine in 2021. GSK said a goal to produce 1 billion doses of adjuvants - with some expected to be delivered to other partners - in 2021 remained in place but was under review.
The Phase I/II study tested the safety, tolerability and immune response of the vaccine in 440 healthy adults across 11 investigational sites in the United States..
This week, Britain started deploying the Pfizer-BioNTech vaccine, jumping ahead of the rest of the world in the race.
Canada has also given the green light for the shot, while a panel of outside advisers to the U.S. Food and Drug Administration on Thursday voted to endorse emergency-use authorization.
Britain's AstraZeneca Plc and Oxford University have also reported late-stage data for their COVID-19 shot, which showed it has an average success rate of about 70%.
Sanofi is working on another COVID-19 vaccine candidate with U.S. company Translate Bio which uses mRNA technology. Phase I trials are expected to start this month.
Reuters
Fri Dec 11 2020
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS Pic
Bintang 'Spider-Man' Tom Holland zahir hasrat kahwini aktres Zendaya
Bintang Spider-Man itu dikatakan sudah berbincang dengan Zendaya untuk berkahwin.
Kertas siasatan 10 individu berkait lelaki Israel dirujuk AGC minggu ini - KP KL
Datuk Rusdi Mohd Isa berkata, perbincangan akan diadakan bagi membuat keputusan terhadap tindakan lanjut yang akan dikenakan terhadap suspek terlibat.
Raja Charles III kembali jalani tugas awam selepas rawatan kanser
Raja Britain, Raja Charles III kembali menjalankan tugas awam selepas kesan positif rawatan kansernya.
LHDN pergiat ‘buru’ syarikat, individu culas bayar cukai
Ujar beliau, LHDN sentiasa memantau data-data sedia ada untuk tindakan sewajarnya.
Program Jelajah Siswa antara pengisian Hawana 2024
Sambutan Hari Wartawan Nasional (Hawana) 2024 pada Mei ini buat julung kalinya akan menyaksikan penglibatan pelajar jurusan komunikasi menerusi Program Jelajah Siswa.
[KEMAS KINI] SPRM ambil keterangan, MB Perlis tegaskan tidak direman
Suruhanjaya Pencegahan Rasuah Malaysia (SPRM) mengesahkan mengambil keterangan Maenteri Besar Perlis kira-kira jam 10 pagi tadi.
Bekas isteri Safee Sali fail tuntutan balas nusyuz
Sebutan semula kes bagi menjawab tuntutan itu oleh plantif ditetapkan pada 11 Jun depan.
Polis selamat mangsa pemerdagangan orang dipaksa bekerja di kelab malam
Polis berjaya menyelamatkan empat wanita warga Filipina yang dipercayai menjadi mangsa pemerdagangan orang.
Pengasas maahad tahfiz didakwa di mahkamah kes liwat pelajar
Tertuduh didakwa meliwat tiga pelajar berusia antara 12 hingga 15 tahun manakala dua daripada mereka merupakan mangsa yang sama.
Pelajar UCLA dakwa universiti lepas tangan
Sebagai pelajar di antara puluhan kampus yang membantah serangan di Gaza, Isabelle Friedman yang memimpin akhbar bebas pelajar UCLA berbicara mengenai cabaran kehidupan harian pelajar dan memberikan liputan berita yang seimbang ketika protes terus meningkat.
Program Jana Wibawa dilaksana selepas dapat persetujuan Jemaah Menteri - Saksi
Mahkamah Sesyen di sini hari ini diberitahu bahawa cadangan mengenai Jana Wibawa telah dibawa ke mesyuarat untuk pertimbangan sebelum Jemaah Menteri memutuskan supaya program itu diteruskan pada 2020.
Kelaparan akut jejaskan 281.6 juta orang tahun lepas - PBB
Tahap bahaya kelaparan akut menjejaskan 281.6 juta orang tahun lepas, tahun kelima berturut-turut bahawa ketakjaminan makanan semakin memburuk.
Hamilton optimis kedudukan lebih baik di GP China
Lewis Hamilton melihat potensi kedudukan yang lebih baik dalam saingan Grand Prix yang kembali ke China buat pertama kali dalam tempoh lima tahun, hujung minggu ini.
'Selfish!' - Fasha Sandha sedih raya di Perlis tak jadi gara-gara dijangkiti COVID-19
Fasha berkata dia mula melakukan pemeriksaan COVID-19 selepas berasa tidak sihat badan dan mengalami bersin tidak henti sejak Raya pertama.
Kes COVID-19 catat penurunan ketara pada ME 14/2024 - KKM
Jumlah kes COVID-19 menurun 97.1 peratus kepada 493 kes pada Minggu Epidemiologi ke-14 (ME 14/2024) iaitu bagi tempoh 31 Mac hingga 6 April lepas berbanding 17,256 kes pada ME 1/2024.
China jadikan pengalaman pencegahan COVID-19 untuk hadapi pandemik masa depan
China akan menjadikan pengalaman dalam pencegahan dan kawalan COVID-19 untuk membuat persediaan yang lebih proaktif untuk menghadapi pandemik masa depan seperti "Penyakit X".
Negara berdepan ketirisan subsidi diesel serius - Amir Hamzah
Negara kini sedang berdepan isu ketirisan subsidi diesel yang serius dan wujud kemungkinan terdapat pihak yang tidak layak masih menikmati subsidi itu, kata Menteri Kewangan II Datuk Seri Amir Hamzah.
Kematian akibat kemalangan jalan raya lebih tinggi daripada COVID-19 - Anthony Loke
PDRM akan mengeluarkan data mengenai kemalangan jalan raya pada setiap hari, bukan setahun sekali seperti diamalkan sebelum ini.
Ismail Sabri ziarah lapan beradik yatim piatu akibat COVID-19
Ismail Sabri tiba kira-kira jam 2 petang di kediaman lapan beradik itu di Taman Adenium, Bukit Beruntung pada Selasa.
Teori konspirasi 'Penyakit X'
Ahli teori konspirasi AS sekali lagi membuat 'keuntungan' selepas PBB memberi amaran tentang wabak lebih berbahaya iaitu 'Penyakit X'.